Kayvaan Mortazavi, MD
Family Medicine · Tucson, AZNPI 1124265285
Payments from drug & device makers
Across 232 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$682
- AbbVie$500
- GSK$443
- Pfizer$418
- Amgen$335
- Lilly USA, LLC$239
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,969100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $682 |
| AbbVie | 28 | $500 |
| GSK | 29 | $443 |
| Pfizer | 27 | $418 |
| Amgen | 22 | $335 |
| Lilly USA, LLC | 15 | $239 |
| Radius Health, Inc. | 7 | $130 |
| Novo Nordisk | 7 | $125 |
| Abbott | 8 | $125 |
| Merck | 5 | $93 |
| Aimmune Therapeutics, Inc. | 5 | $75 |
| Novartis | 4 | $74 |
| Corcept Therapeutics | 4 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $66 |
| Phathom Pharmaceuticals, Inc. | 4 | $64 |
| Astellas Pharma US Inc | 3 | $58 |
| Recordati_rare_diseases_inc. | 3 | $54 |
| Eisai Inc. | 3 | $49 |
| Exact Sciences | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Dexcom, Inc. | 2 | $31 |
| Almatica Pharma LLC | 2 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Nevro Corp. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Insulet Corporation | 1 | $21 |
| Averitas Pharma Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $15 |
How this compares
$3,969 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $94,157 |
| JanuviaSitagliptin Phosphate | 52 | $73,962 |
| JardianceEmpagliflozin | 37 | $57,839 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $40,829 |
| MounjaroTirzepatide | 31 | $33,193 |
| OzempicSemaglutide | 19 | $27,255 |
| TrulicityDulaglutide | 14 | $21,933 |
| Teriparatide | 12 | $20,209 |
| XareltoRivaroxaban | 11 | $17,081 |
| FarxigaDapagliflozin Propanediol | 13 | $16,713 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $15,618 |
| LinzessLinaclotide | 18 | $15,420 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $14,855 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $12,089 |
| Spiriva HandihalerTiotropium Bromide | 13 | $12,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $418 | $94,15776 claims |
| MerckJanuvia, Lagevrio (Eua), Belsomra | $93 | $87,74077 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $443 | $73,83693 claims |
| Boehringer IngelheimJardiance | $15 | $57,83937 claims |
| Lilly USA, LLCMounjaro, Trulicity | $239 | $55,12645 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $682 | $39,95949 claims |
| Novo NordiskOzempic | $125 | $27,25519 claims |
| AbbVieLinzess | $500 | $15,42018 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $3,202365 claims |
| Sanofi-aventis U.S. LLCLantus | $23 | $2,40520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tucson
- Dena PetersenTucson$14.7M
- John McGettiganTucson$8.3M
- Kevin PoundsTucson$1.9M
- Thili KulatilakeTucson$1.8M
- Judith BrownTucson$399K
- Hannah LeslieTucson$228K
- Charles MichieliTucson$111K
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.